Literature DB >> 24982073

Monitoring of trough plasma ganciclovir levels and peripheral blood cytomegalovirus (CMV)-specific CD8+ T cells to predict CMV DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients.

Estela Giménez1, Carlos Solano2, José Ramón Azanza3, Paula Amat4, David Navarro5.   

Abstract

It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell transplant recipients. In this observational study, including 13 episodes of CMV DNAemia treated with intravenous (i.v.) GCV or oral valganciclovir, we showed that monitoring trough plasma GCV levels does not reliably predict response to therapy. Rather, immunological monitoring (pp65 and immediate-early [IE]-1-specific gamma interferon [IFN-γ]-producing CD8+ T cells) appeared to perform better for this purpose.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24982073      PMCID： PMC4135831          DOI： 10.1128/AAC.02953-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS.

Authors:  C Piketty; C Bardin; J Gilquin; V Mahe; M D Kazatchkine; F Chast
Journal:  J Infect Dis       Date:  1996-07       Impact factor: 5.226

2.  Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients.

Authors:  Concepción Gimeno; Carlos Solano; José C Latorre; Juan C Hernández-Boluda; María A Clari; María J Remigia; Santiago Furió; Marisa Calabuig; Nuria Tormo; David Navarro
Journal:  J Clin Microbiol       Date:  2008-08-27       Impact factor: 5.948

3.  Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.

Authors:  N Tormo; C Solano; I Benet; M A Clari; J Nieto; R de la Cámara; J López; N López-Aldeguer; J C Hernández-Boluda; M J Remigia; A Garcia-Noblejas; C Gimeno; D Navarro
Journal:  Bone Marrow Transplant       Date:  2009-07-20       Impact factor: 5.483

4.  Development and validation of a sensitive method for the determination of ganciclovir in human plasma samples by reversed-phase high-performance liquid chromatography.

Authors:  M A Campanero; B Sadaba; E García-Quetglas; J R Azanza
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-03-20

5.  Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.

Authors:  N Tormo; C Solano; I Benet; J Nieto; R de la Cámara; J López; A Garcia-Noblejas; B Muñoz-Cobo; E Costa; M A Clari; J C Hernández-Boluda; M J Remigia; D Navarro
Journal:  Bone Marrow Transplant       Date:  2011-01-17       Impact factor: 5.483

6.  Low systemic ganciclovir exposure and preemptive treatment failure of cytomegalovirus reactivation in a transplanted child.

Authors:  Julie Autmizguine; Yves Théôret; Elise Launay; Michel Duval; Céline Rousseau; Bruce Tapiéro; Guy Boivin; Philippe Ovetchkine
Journal:  J Popul Ther Clin Pharmacol       Date:  2011-05-10

7.  A simple, sensitive determination of ganciclovir in infant plasma by high-performance liquid chromatography with fluorescence detection.

Authors:  Terumitsu Yoshida; Ryohei Takahashi; Koichi Imai; Hiroshi Uchida; Yasutoshi Arai; Tsutomu Oh-ishi
Journal:  J Chromatogr Sci       Date:  2010-03       Impact factor: 1.618

8.  Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation.

Authors:  Hermann Einsele; Pierre Reusser; Martin Bornhäuser; Peter Kalhs; Gerhard Ehninger; Holger Hebart; Yves Chalandon; Nicolaus Kröger; Bernd Hertenstein; Frank Rohde
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

9.  Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection.

Authors:  Nuria Tormo; Carlos Solano; Isabel Benet; José Nieto; Rafael de la Cámara; Ana Garcia-Noblejas; María Angeles Clari; Marifina Chilet; Javier López; Juan Carlos Hernández-Boluda; María José Remigia; David Navarro
Journal:  J Med Virol       Date:  2010-07       Impact factor: 2.327

10.  Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.

Authors:  Nancy Perrottet; Oriol Manuel; Frédéric Lamoth; Jean-Pierre Venetz; Roland Sahli; Laurent A Decosterd; Thierry Buclin; Manuel Pascual; Pascal Meylan
Journal:  BMC Infect Dis       Date:  2010-01-06       Impact factor: 3.090
View more
  4 in total

1.  A Systematic Review of the Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Ganciclovir/Valganciclovir in Allogeneic Haematopoietic Stem Cell Transplant Patients.

Authors:  Philip Roland Selby; Sepehr Shakib; Sandra L Peake; Morgyn S Warner; David Yeung; Uwe Hahn; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-01-30       Impact factor: 6.447

Review 2.  Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.

Authors:  Mohd H Abdul-Aziz; Jan-Willem C Alffenaar; Matteo Bassetti; Hendrik Bracht; George Dimopoulos; Deborah Marriott; Michael N Neely; Jose-Artur Paiva; Federico Pea; Fredrik Sjovall; Jean F Timsit; Andrew A Udy; Sebastian G Wicha; Markus Zeitlinger; Jan J De Waele; Jason A Roberts
Journal:  Intensive Care Med       Date:  2020-05-07       Impact factor: 17.440

3.  Valganciclovir-Ganciclovir Use and Systematic Therapeutic Drug Monitoring. An Invitation to Antiviral Stewardship.

Authors:  Alicia Galar; Maricela Valerio; Pilar Catalán; Xandra García-González; Almudena Burillo; Ana Fernández-Cruz; Eduardo Zataráin; Iago Sousa-Casasnovas; Fernando Anaya; María Luisa Rodríguez-Ferrero; Patricia Muñoz; Emilio Bouza
Journal:  Antibiotics (Basel)       Date:  2021-01-15

4.  Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads.

Authors:  Anne-Grete Märtson; Marieke G G Sturkenboom; Marjolein Knoester; Tjip S van der Werf; Jan-Willem C Alffenaar; William Hope
Journal:  J Antimicrob Chemother       Date:  2022-02-02       Impact factor: 5.790
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.